The human gene, human giant larvae (Hugl-1/Llg1/Lgl1) has significant homology to the Drosophila tumour suppressor gene lethal(2)giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that binds Myosin II and is involved in maintaining cell polarity and epithelial integrity. The human protein, Hugl-1 contains several conserved functional domains found in Lgl, suggesting that these proteins may have closely related functions. Whether loss of Hugl expression plays a role in human tumorigenesis has so far not been extensively investigated. Thus, we evaluated tumour tissues from 94 patients undergoing surgery for colorectal cancer (CRC) for loss of Hugl-1 transcription and compared our findings with the clinical data from each of these patients. We found that Hugl-1 was lost in 75% of tumour samples and these losses were associated with advanced stage and particularly with lymph node metastases. Reduced Hugl-1 expression during the adenoma-carcinoma sequence occurring as early as in colorectal adenomas was detected by both immunohistochemical and reverse transcriptionpolymerase chain reaction analysis. Functional assays with ecdysone-inducible cell lines revealed that Hugl-1 expression increased cell adhesion and decreased cell migration. Our studies thus indicate that downregulation of Hugl-1 contributes to CRC progression.
Introduction
Colorectal cancer (CRC) ranges among the three most frequent malignancies in western countries, being surpassed only by lung and prostate cancer in men and by lung and breast cancer in women (Parkin et al., 1993; Parker et al., 1996; Micheli et al., 2002) . While hereditary syndromes such as familial adenomatous polyposis (FAP) and hereditary nonpolyposis colon cancer (HNPCC) affect only a minority of CRC patients, in the majority of patients (85%) carcinogenesis is sporadic (Houlston et al., 1992) . The adenomacarcinoma sequence, first proposed by Fearon and Vogelstein in 1990 , describes the development of sporadic CRC from precancerous adenomatous mucosal lesions (Vogelstein and Kinzler, 1993) . Some of the molecular determinants of this sequence have been identified and include mutations in oncogenes (K-ras) (Cho and Vogelstein, 1992; Vogelstein and Kinzler, 1993; Guanti and Bukvic, 2000) , as well as the tumoursuppressor genes APC, DCC, p53 and, more recently Smad2 and Smad4 (Takagi et al., 1998; Roth et al., 2000; Boulay et al., 2001) .
Loss of lethal giant larvae (lgl) in Drosophila results in the neoplastic transformation of the brain hemispheres and the imaginal discs which lose their epithelial monolayer stucture and grow in large amorphous masses resembling mammalian carcinomas (Agrawal et al., 1995; Gateff, 1978) . Upon transplantation into wild-type recepients, these tumorous tissues grow and migrate to distant sites, thus behaving like mammalian metastatic tumours (Woodhouse et al., 1994; Woodhouse et al., 1998) . Lgl-induced metastases overexpress type IV collagenase and NDP kinase, thus showing some of the biochemical features of metastatic tumours in humans (Timmons et al., 1993; Woodhouse et al., 1994) . Homologues of lgl have been identified in many species including man, mouse, insect, worm, slime mold and yeast (Strand, 1998) . Indeed, the function of Lgl is conserved as evidenced by rescue of the Drosophila lgl mutation with its human homologue, Hugl-1, and the complementation of the yeast mutations by the human and Drosophila proteins (Kagami et al., 1998; Larsson et al., 1998; Grifoni et al., 2004) . Biochemical and genetic analyses have shown that the Lgl proteins are components of the cytoskeleton and interact with nonmuscle myosin II (Strand et al., 1994a, b; Ohshiro et al., 2000) . Recently, evidence was provided that mammilian Lgl forms complexes with Par6/Par3/atypical PKC (aPKC) regulating epithelial cell polarity (Yamanaka et al., 2003) . Upon cell-cell contact induced cell polarization, Lgl is phosphorylated by aPKC resulting in a dissociation of Lgl from Par6/aPKC followed by an accumulation of Lgl along the basolateral membrane where it contributes to the formation of the basolateral membrane domain (Plant et al., 2003; Tanentzapf and Tepass, 2003) .
The Hugl-1 gene maps to the short arm of chromosome 17 in a pericentromeric region, 17p11.2-12, which may contain a potential cancer susceptibility gene for primitive neuroectodermal tumours (PNETs) (Strand et al., 1995; Scheurlen et al., 1997) . Recent molecular characterization of this region identified the presence of a cluster of deletion breakpoints in PNETs, but to date, a role of Hugl-1 in human cancer remains largely unknown (Scheurlen et al., 1999) . Interestingly, Hugl-1 maps within the 17p interstial deletion detected in mentally retarded children with Smith-Magenis syndrome (SMS) (Chen et al., 1995; Koyama et al., 1996; Scheurlen et al., 1997) . Although the molecular pathology of SMS is not yet unraveled, it is thought that haploinsufficiency of a set of genes within the SMS deletion gives rise to the abnormalities found in SMS patients. The intense expression of Hugl-1 in the brain suggests a potential role in SMS and perhaps PNETs (Strand et al., 1995) . Recent studies using knockout mice support an essential role of the mgl-1/Lgl1 gene, the mouse orthologue of Hugl-1, in the brain (Klezovitch et al., 2004) . Mice that are homozygously mutated for mgl-1/Lgl1 die neonatally and display severe hydrocephaly. Histologically, the neuroepithilia is severely disrupted and forms rosette-like structures.
We have recently investigated a panel of 60 human solid tumours and reported that Hugl-1 is reduced or absent in 62% of the samples examined (Grifoni et al., 2004) . The present study was performed to evaluate the role of Hugl-1 in human colon carcinogenesis. Therefore, we screened the transcription profiles of Hugl-1 in 15 different human cancer cell lines and 94 colorectal carcinomas and performed IHC stainings of colorectal mucosa, adenomas, cancers and metastases. In addition, functional assays with a Hugl-1-inducible cell line were performed to characterize the biological effects of Hugl-1.
Results

Loss of Hugl-1 transcription in human cancer cell lines
Hugl-1 was expressed in renal (Hek-293) and lung (LC103, A549), hepatocellular (Hep3B, Huh7) and cervical (HeLa) cancer cell lines (Figure 1 ). In contrast, Hugl-1 bands were absent in the hepatocellular cancer cell line HepG2. Hugl-1 was intensely expressed in CRC Figure 1 Alterations in Hugl-1 expression in diverse human cancer cell lines, colorectal muscosa and CRC. A series of samples are shown from the total analysed: 19 mucosas, 10 adenomatous polyps, and 94 CRC and 14 liver metastases analysed by reverse transcription-polymerase chain reaction (RT-PCR). The relative Hugl-1 expression was scored as follows: expressed, reduced or negative as indicated, respectively, by black, grey, or white shading of boxes depicted below each panel. The b-actin expression level is shown as a standard reaction control cell lines ISR1 and SW480, whereas further CRC cell lines (SW620, HT29, DLD-1, LS174, CaCo, HDC 8) displayed variable intensities of the Hugl-1 product, ranging from weak to absent.
Loss of Hugl-1 transcription during the adenoma carcinoma sequence
The reduced expression of Hugl-1 in the colon carcinoma cells lines prompted us to examine Hugl-1 transcription in a series of human CRC tissues ( Figure 1 , Table 1 ). To locate the loss of the Hugl-1 transcription within the adenoma-carcinoma pathway and to correlate loss of Hugl-1 with patient-and tumour characteristics, 19 nonneoplastic mucosas, 10 adenomatous polyps, 94 colorectal primary cancers and 14 liver metastases were screened by RT-PCR for actin and Hugl-1 transcripts. Actin transcription was comparable in all samples. Hugl-1 transcription was observed in all 19 samples of non-neoplastic mucosa (loss: 0%); but was lost in six of 10 adenomatous polyps (60%), 70 of 94 colorectal carcinomas (75%) and four of 14 hepatic metastases (72%).
Tumour characteristics and patient profile
Average age of all CRC patients was 67.5 years. Colon carcinoma samples were from 59% male and 41% female patients. In all, 33% of all tumours were located in the right colon and 67% in the left colon and rectum. By histopathological grading, most tumours (83%) were moderately differentiated G2 as compared to less differentiated G3 (17%). The resection margins were free of residual microscopic or macroscopic tumour (RO) in 85% of all cases. Venous invasion was histologically detected in only a fifth of the cases (V0, 79%; V1, 21%), whereas lymph vessel invasion was described in most patients (L0, 13%; L1, 87%). According to the TNM classification, fewer tumours were classified T1 (1%), T2 (22%) or T4 (11%), than T3, which was diagnosed in 66% of all tumours. By histological and clinical assessment, half of the patients showed no lymph node involvement (N0, 52%; N þ , 48%) and most had no distant metastases (M0, 83%; M1, 17%). Advanced UICC stages III and IV were present in 55% of all patients.
Loss of Hugl-1 versus tumour and patient characteristics
The location of CRCs within the six colorectal segments showed no correlation with loss of Hugl-1 (Table 2) . According to the UICC classification, loss of Hugl-1 was significantly associated with advanced (higher) UICC stages III or IV (P ¼ 0.0043; Table 2 ) as compared to UICC I or II stages. TNM classification revealed no significant correlation between loss of Hugl-1 and either T-or M-status. In contrast, there was a significant association with lymph node metastases (N-status; P ¼ 0.034) and a possible trend with lymph vessel invasion (L-status; P ¼ 0.16). The histological grading of tumours and the presence of venous invasion were not related to Hugl-1 status. Loss of Hugl-1 showed no association with gender. Surprisingly, a small, albeit statistically significant correlation was observed when analysing the age of patients: patients with Hugl-1-positive tumours (64.5 years) were 4.1 years younger than Hugl-1-negative cancer patients (68.6 years; P ¼ 0.035). These results reveal a significant association between a loss of Hugl-1 in CRC samples and lymphatic dissemination.
Immunofluorescence analysis of Hugl-1 expression in CRC cell lines
Immunofluorescence observations revealed varying staining intensities of Hugl-1 in different human CRC cell lines (Figure 2 ). While SW480 cells depicted an intense cortical and less intense cytoplasmic Hugl-1 
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Reduced expression of Hugl-1 in colorectal cancer CC Schimanski et al staining, Hugl-1 staining appeared weaker and more diffuse in Caco-2 and HT-29 cells. In SW620 cells, a metastatic derivative of SW480, Hugl-1 staining was reduced and more diffuse than in SW480 cells. Interestingly, Hugl-1 expression as described by immunofluorescence observations positively correlated with the Hugl-1 transcription profile generated by RT-PCR.
Immunohistochemical analysis of Hugl-1 expression in CRC samples
To examine Hugl-1 expression in vivo, normal colorectal mucosa, adenoma, carcinoma and associated metastases of the liver and lymph nodes were immunostained with an anti-Hugl-1 antibody. Representative sections are presented in Figure 3 . Hugl-1 immunohistochemistry revealed a strong cortical and a weaker cytoplasmatic staining of human colorectal mucosa enterocytes in all samples (5/5). Hugl-1 accumulated beneath the luminal membrane of the respective enterocytes. Interestingly, Hugl-1 expression of enterocytes was strongest at the apical segments and almost absent in the basal segments of the crypt. Hugl-1 expression in adenoma as compared with human mucosa was focal and weaker in five of eight adenomas analysed. Colorectal carcinoma depicted a weak to absent expression of Hugl-1 in four of five samples. In all metastatic lesions (8/8), a further reduction of Hugl-1 expression was seen with cells revealing only very weak to no Hugl-1 staining at all. In summary, these data show an inverse correlation between protein expression and tumour progression as the amount of Hugl-1 protein staining decreases from normal colonic mucosa and colon adenoma to metastatic colon carcinoma in vivo.
Functional analysis using Hugl-1-GFP inducible 293 cell line Based on our findings that loss of Hugl-1 is associated with advanced disease and metastasis, we analysed the behavior of cells expressing Hugl-1 from an ecdysone inducible promoter for such parameters as growth, cell cycle status, migration and de-adhesion. First, we established stable cell lines in which Hugl-1-GFP is inducible by addition of the ecdysone analogue, ponasterone A. Western blot analysis confirmed the inducible expression of the Hugl-1-GFP fusion protein with the expected molecular mass (Figure 4a ). 293EcR-Hugl-1-GFP cells induced with ponasterone revealed an intense staining with a predominantely cortical localization of Hugl-1-GFP fusion protein ( Figure 4B ). This staining pattern resembled very closely that which we observed in cell lines (see Figure 2 ) and appeared even more pronounced at cell-cell contacts. Next, we analysed whether the expression of Hugl-1 affected cell growth and cell cycle status. Treatment with ponasterone as compared to controls resulted in no significant changes in proliferation in 293EcR and 293EcR-Hugl-1-GFP cell lines (Figure 5a) . A slight growth inhibition, which has been described previously, upon treatment with ponasterone was observed in both 293EcR and 293EcR-Hugl-1-GFP cell lines but was independent of Hugl-1-GFP expression (Yam et al., 2001) . Total protein analysis after 5 days of cell culture revealed following results: 293EcR-Hugl-1-GFP: solvent control: 130 (76.2) mg protein/well; ponasterone: 113 (710.2) mg protein/well. 293EcR: solvent control 177 (725) mg protein/well; ponasterone: 150 (713) mg protein/well (P>0.05, not significant). Cell cycle status was determined in logarithmic growing cultures using FACS.
Comparison of Hugl-1-GFP-induced cultures to uninduced or to 293EcR cells treated with or without ponasterone resulted in no significant changes in cell cycle status (Figure 5b) . Results for 293EcR-Hugl-1-GFP cells were as follows: solvent control: 50.4% G1 and 45.1% S/G2; ponasterone treatment: 52.6% G1 and 43.6% S/G2. Results for 293EcR cells were: solvent control 47.8% G1 and 48.1% S/G2; ponasterone treatment: 51.9% G1 and 44.5% S/G2. These results indicate that Hugl-1 does not directly affect growth or the cell cycle.
The correlation between the loss of Hugl-1 and lymphatic metastasis prompted us to investigate the influence on motility of cells induced to express Hugl-1-GFP. Using a trans-chamber assay, cells that were induced to express Hugl-1-GFP displayed significantly During cultivation of induced 293EcR-Hugl-1-GFP cells that had reached confluency, we observed that cell sheets were resistant to handling. Indeed, after several days of confluency cells shedded into the medium were routinely less for Hugl-1-GFP cultures compared to uninduced cultures or 293EcR cells. To assay this phenomenon, we applied mechanical stress and measured the cells detaching into the medium. Before cells were exposed to mechanic stress, no difference of cell detachment was detected (ponasterone 7 mM: 60 RLU IE (71); solvent control: 55 RLU (73); not significant (Figure 5d ). After 2 min of mechanic stress, a significant increase of cell detachment to the medium was observed for solvent-treated control cells, but not for Hugl-1-GFP-induced cells (ponasterone 7 mM: 136 RLU (717); solvent control: 887 RLU (7326); Pr0.01). Ponasterone did not impact de-adhesion of 293EcR cells (data not shown). Taken together, Hugl-1 expression does not affect cell proliferation or cell cycle status, but decreases cell migration and increases cell adhesion. These results suggest that reduced Hugl-1 expression may destablize epithelial structures and contribute to cancer cell dissemination and ultimately, tumour progression.
Discussion
In this study, we investigated the transcription profile of Hugl-1, the human homologue of the Drosophila tumour Reduced expression of Hugl-1 in colorectal cancer CC Schimanski et al suppressor lgl, in a series of human cancer cell lines, adenomatous polyps, colorectal tumour tissues, adjacent non-neoplastic mucosa and hepatic metastases. We initiated this study to determine whether Hugl-1 might fulfill some of the criteria of a tumour suppressor gene in humans. Specifically, we were interested to know whether Hugl-1 transcription is altered during CRC progression and whether loss of Hugl-1 expression correlates with tumour or patient characteristics. Our data indicate a link to CRC and support a putative tumour suppressor function for Hugl-1 for the following reasons: (1) We found Hugl-1 transcription was reduced in six of eight colon carcinoma cell lines examined; SW620 cells originating from a metastatic lesion revealed a dramatic decrease of Hugl-1 expression and transcription as compared to parental SW480 cells originating from the primary tumour. (2) Hugl-1 transcription was prevalent in all of the 19 examined non-neoplastic mucosa samples, but reduced or lost in a high percentage of adenomatous polyps (60%), CRCs (75%) and hepatic metastases originating from CRC (72%). (3) There was a statistically significant correlation for a loss of Hugl-1 and disease progression and lymph node mestastasis as well as a trend for lymph vessel invasion. (4) Hugl-1 immunohistochemistry revealed an epithelial staining and an inverse correlation between protein expression and tumour progression. The amount of Hugl-1 protein staining decreased from normal colonic mucosa and colon adenoma to metastatic colon carcinoma. Interestingly, glandular differentiated parts of CRC samples depicted a weak but luminal staining of Hugl-1, which was completely absent in dedifferentiated areas of CRC. (5) Induction of Hugl-1 protein resulted in a significant decrease in cell migration and stress-induced cellular detachment, but did not influence proliferation. Thus, downregulation of Hugl-1 may contribute to the dissemination of cancer cells.
These results taken with our previous studies provide the first indications for a tumour suppressor role of Hugl-1 gene in human cancers. Further, they justify additional studies to determine if downregulation or loss of Hugl-1 occurs in tumours derived from other tissues, as well as investigating the mechanisms by which Hugl-1 is inactivated.
The downregulation or loss of Hugl-1 in adenomatous polyps is intriguing as it suggests that Hugl-1 is dysregulated early during the adenoma carcinoma sequence resembling the inactivation of the tumour suppressor gene APC. Although we have only examined a limited number of adenomatous polyps for Hugl-1 gene expression, further studies will determine more precisely whether reduction or loss of Hugl-1 expression occurs in tubular, tubulo-villous or villous adenomas, the latter of which are more prone to develop into carcinomas.
Hugl-1 was identified in a polarity complex with Par6 and aPKC, which plays a critical role in maintaining epithelial cell polarity (Plant et al., 2003; Yamanaka et al., 2003) . Recent studies in Drosophila have shown that in addition to lgl, two other well-characterized tumour suppressors, dlg, and scrib are part of a genetic pathway functioning at the membrane cytoskeleton maintaining epithelial structure and polarity . Moreover, in humans, the homologue of Dlg, hDlg binds the tumour suppressor APC and the complex hDLG-APC negatively regulates the cell cycle supporting a tumour suppressor role for hDlg (Ishidate et al., 2000) . hDlg is downregulated in both cervical and gastric cancer, and somatic mutations in highly conserved residues as well as altered expression levels have been found in mammary ductal carcinoma supporting a role of hDlg in these cancers (Watson et al., 2002; Fuja et al., 2004; Lin et al., 2004) . The human genes hDlg, hScrib and Hugl-1 are capable of rescuing their respective Drosophila mutation demonstrating a conserved tumour suppressor function for these genes (Thomas et al., 1997; Dow et al., 2003; Grifoni et al., 2004) . Taken together with the data presented in this paper, evidence is accumulating that the human homologues of the Dlg, Scrib and Lgl pathway of Drosophila may be involved in a common pathway in humans, whose inactivation plays a role in cancer.
Although, the multistage model of colorectal tumourigenesis involving mutations of the oncogenes K-ras, APC and the tumour suppressor gene p53 first proposed by Fearon and Volgelstein in 1990 has been extensively supported, it is widely accepted that our knowledge is still incomplete. Recent studies in a large cohort of CRC patients have shown that K-ras and p53 mutations are largely mutually exclusive events, and less than 50% of tumours contained multiple mutations in either K-ras, Reduced expression of Hugl-1 in colorectal cancer CC Schimanski et al p53 or APC and less than 7% of tumours contained mutations in all three genes (Smith et al., 2002; Leslie et al., 2003) . Moreover, 39% of the tumours in this cohort contained mutations in only one gene. Thus current paradigms must consider that distinct and alternative pathways for colorectal tumorigenesis exist and the search for candidate genes involved in these pathways is not finished. As our findings that Hugl-1 is transcriptionally lost in 75% of the colorectal tumours are in the order of magnitude in which alterations in K-ras, p53 or APC have been reported, a role for Hugl-1 in colorectal tumourigenesis is likely. Our analysis focused on transcriptional loss of Hugl-1, thus we would not have detected mutations in the coding regions potentially inactivating Hugl-1. Thus, it is possible that a higher percentage of tumours may have effectively lost Hugl-1, or alternatively, Hugl-1 is involved in certain types of tumours. Additional studies will be necessary to clarify these points.
The development of CRCs is associated with progressive loss of epithelial structure, cell polarity and decreased cell-cell contact. The available biochemical information on Hugl proteins from studies in Drosophila and cultured human cells support the notion that Hugl-1 contributes to maintenance of epithelial integrity through its cytoskeletal interactions. Taken together with the results presented in this paper, a role for Hugl-1 in human cancer is predicted thus warranting further investigations.
Material and methods
Cell culture
The following human cancer cell lines were studied: human epithelial kidney cells (293), hepatocellular cancer (HepG2, Hep3B, Huh7), cervical cancer (HeLa), colon cancer (HT29, DLD1, SW620, ISR1, LS174, CaCo, HDC 8, SW480) and lung cancer (LC103, A549). All cell lines were cultured in DMEM supplemented with 10% FCS.
Tissue source and storage
Tumour samples and non-neoplastic mucosa were obtained from 94 patients undergoing elective surgery for CRC. The tumour tissue originated from the centre of the tumour, whereas the mucosa was taken from the proximal margin of the resectate. Furthermore, samples were obtained from adenomatous polyps resected endoscopically in 10 patients. Migration of 293EcR and 293EcR-Hugl-1-GFP cells was determined by a transwell migration assay. Hugl-1-GFP induction decreased migration to the lower chamber. (d) Induction of Hugl-1-GFP increases resistance to mechanical stress. Confluent cultures of 293EcR-Hugl-1-GFP cells cultivated with and without ponasterone were exposed to mechanical stress for 2 min on an orbital shaker set at 1000 r.p.m. Cells shed into the supernatant were quantified by a luminescence cell viability assay Finally, samples were obtained from liver metastases in 14 patients with limited hepatic disease. Informed consent was obtained before the respective tissue was collected. All tissues were stored in cryovials, shock frozen in liquid nitrogen immediately after extirpation and stored at À801C until further processing.
RNA Isolation and RT-PCR
RNA isolation was performed using the 'Qiagen RNeasy Kit' according to the manufacturer's recommendations (Qiagen, Hilden, Germany). Transcription of actin and Hugl-1 was analysed by a two-step RT-PCR: RT was performed with 2 mg of RNA (20 ml total volume; Ominscript RT Kit, Qiagen according to the recommendations of the manufacturer. In total, 1 ml of the cDNA (100 ng) was used as a template for the specific PCR reactions. Primers applied were b-Actin-forward: 5 0 -TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3 0 and b-Actin-reverse: 5 0 -CTA GAA GCA TTT GCG GTG GAC GAC GGA GGG-3 0 (661 base pairs (bp) fragment), Hugl-1-forward: 5 0 -AAG CTG TGG GCC CGC ATT GTG A-3 0 and Hugl-1-reverse: 5 0 -GTC CTG GAG GAG GTC TAT GAT A-3 0 (450 bp fragment). For amplification, a ''DNA Engine PTC200'' (MJ Research, Watertown, USA) thermocycler was used. Cycling conditions of the respective PCR were as follows: initial denaturation (4 min at 951C), followed by the respective number of cycles (b-actin: 30; Hugl-1: 36) of denaturation (1 min at 941C), annealing (1 min; b-actin: 521C; Hugl-1: 621C) and elongation (2 min at 721C). After the last cycle a final extension (10 min at 721C) was added and thereafter the samples were kept at 41C. In total 15 ml of the products were analysed by 1.8% agarose gel, stained with ethidium bromide and viewed under UV light (Herolab, Wiesloch, Germany).
Immunofluorescence CRC cell lines SW480, SW 620, Caco-2 and HT-29 were grown on chamber slides for 2 days, fixed with 3% paraformaldehyde/PBS for 15 min, washed with PBS/0.1% Triton X and covered with blocking solution (PBS/0.1% Triton X/3% BSA) for 1 h. Thereafter, cells were incubated with a polyclonal rabbit-anti-Hugl-1 antibody (1 : 200) overnight at 41C. After washing the cells, they were incubated with the secondary antibody (Cy3-conjugated Affinipure goat anti-rabbit IgG F(ab) antibody (1 : 1000, Jackson Immunoresearch, USA) and Hoechst 33342 (1 : 5000, Molecular Probes, USA) for 30 min. After mounting, images were collected by confocal laser scanning micrcoscopy using a Zeiss LSM 510-UV.
Immunohistochemistry
Paraffin-embedded tissue sections from patients with normal colon ( Â 5), colon adenoma ( Â 8, Â 5 low-grade intraepithelial neoplasia and Â 3 high-grade intraepithelial neoplasia) and carcinoma ( Â 5), and associated metastases in liver ( Â 5) and lymph nodes ( Â 3) were screened for Hugl-1 protein expression by immunohistochemistry. The tissues were deparaffinized, rehydrated and subsequently incubated with primary polyclonal rabbit Hugl-1 antibody (1 : 500) over night at 41C. The secondary antibody (biotin-labelled anti-rabbit, DAKO, Germany) was incubated for 30 min at room temperature, followed by incubation with streptavidin-POD (DAKO, Germany) for 30 min. Antibody binding was visualized using AEC-solution (DAKO, Germany). Finally, the tissues were counterstained by haemalaun solution (DAKO, Germany). The evaluation of the staining was performed semiquantitatively by light microscopy. The intensity of staining was graded as followed: negative: 0, weak: 1, medium: 2, strong: 3.
Establishment of Hugl-1-GFP-expressing clones
We used 293 cell line to establish a variant line in which expression of a Hugl-1-GFP fusion protein is controlled by ecdysone or its analogue, Ponasterone A (Invitrogen, USA). The cDNA containing the complete open reading frame of Hugl-1-GFP was cloned into an ecdysone inducible mammalian expression vector, pIND (SP1)/neomycin (Invitrogen, USA). 293EcR (stably transfected with pVgRxR/Zeocin regulator vector) were seeded in six-well plate at 80% confluency. The cells were transfected with pIND-Hugl-1-GFP plasmid by lipofectamine 2000 reagent according to the recommendations of the manufacturer (Invitrogen, USA). The transfected cells were selected in medium containing G418 (400 mg/ml) and Zeocin (400 mg/ml). Stable clones which grew after about 4 weeks of selection, were picked and analysed by Western blot. Western blots were developed using a polyclonal rabbit-anti-Hugl-1 antibody (1 : 2000) and visualized by CDPstar detection system (Tropix, Applied Biosystems, Bedford, MA, USA).
Proliferation assays
5 Â 10 3 cells (293EcR-Hugl-1-GFP or 293EcR) were plated in 96-wells. After seeding, cells were either induced with ponasterone (7 mM; dissolved in ethanol) or cultured with the equivalent amount of solvent added to the medium. The increase of cells per well was determined daily by measuring total protein levels in each well using Micro BCA Protein Assay (Pierce, Rockford, IL, USA) according to the manufacturer's instructions. Absorbance was read at 562 nm in an ELISA reader (Safire, Tecan, Germany). The experiment was performed in quadruplicate and repeated three times.
Cell cycle analysis
The respective cells were seeded in six wells at 60-70% confluency and treated with either 7 mM ponasterone for induction or the equivalent volume of solvent as control for 2 days. All cells were washed with PBS and fixed in 70% ethanol. This was followed by staining with propidium iodide (50 ng/ml). DNA fluorescence was measured in a FACScan according to a published method (Krishan, 1975; Nicoletti et al., 1991) .
Migration assays
Migration of 293EcR-Hugl-1-GFP or 293EcR cells was assayed with 24-well HTS FluoroBlok inserts (8 mM pore size; Becton Dickinson, USA). Membranes were previously covered with laminin (10 mg/ml, 30 min, room temperature, Sigma, Germany) and blocked with albumin (2%, over night, 41C, Serva, Germany). Hugl-1-GFP was induced for 48 h (7 mM ponasterone), whereas control cells were treated with the equivalent amount of solvent before initiation of the assay. 2 Â 10 4 cells were resuspended in serum-free DMEM and added to the upper chamber. DMEM medium with 20% FCS and 70 ng/ml SDF-1a was added to the lower chamber. Chambers were incubated for 24 h at 371C in a humid atmosphere of 5% CO 2 . After incubation, the amount of invaded and migrated cells in the lower chamber was determined by luminescence assay (Celltiter-Glo, Cell Viability assay, Promega, USA) according to the recommendations of the manufacturers. Each condition was performed in triplicate.
De-adhesion assay
De-adhesion of 293EcR-Hugl-1-GFP cells and 293EcR cells was assayed by applying a mechanical stress. The respective cells were seeded in six wells and treated with either 7 mM ponasterone for induction of Hugl-1-GFP or the equivalent volume of solvent as control. At 7 days after reaching confluency, mechanical stress was applied as follows: cells were washed with PBS and covered with 1 ml of new DMEM medium. The culture dish was fixed on a short stroke orbital shaker (IKA-Schu¨ttler MTS4, Janke and Kunkel, Staufen, Germany) and exposed to 1000 r.p.m. for 2 min. Cells detached into the DMEM medium was quantified by luminescence assay (Celltiter-Glo, Cell Viability assay, Promega, USA) according to the recommendations of the manufacturers. Luminescence, indicating living cells in the medium, was detected by an ELISA-reader (Spectra Fluor Plus, Tecan, Germany). The assays were performed in triplicate.
Statistics
The age of patients was compared after calculating the mean and standard deviation of the respective subgroups using the nonparametric Wilcoxon test. The w 2 test was used to compare all other patient and tumour characteristics by group. The t-test was applied to compare results obtained from the functional assays. For all tests, a P-value of o0.05 was considered significant. Abbreviations bp, base pair; CRC, colorectal carcinoma; Hugl, human giant larvae; lgl, lethal giant larvae; PCR, polymerase chain reaction; RT, reverse transcription.
